{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,19]],"date-time":"2026-06-19T20:43:44Z","timestamp":1781901824004,"version":"3.54.5"},"reference-count":27,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2015,10,1]],"date-time":"2015-10-01T00:00:00Z","timestamp":1443657600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2015,10]]},"DOI":"10.1016\/j.eururo.2015.04.032","type":"journal-article","created":{"date-parts":[[2015,5,16]],"date-time":"2015-05-16T03:14:41Z","timestamp":1431746081000},"page":"570-577","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":57,"title":["Impact of Bone-targeted Therapies in Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302"],"prefix":"10.1016","volume":"68","author":[{"given":"Fred","family":"Saad","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Shore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrik","family":"Van Poppel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dana E.","family":"Rathkopf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew R.","family":"Smith","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johann S.","family":"de Bono","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Logothetis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"de Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karim","family":"Fizazi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter F.A.","family":"Mulders","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Mainwaring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John D.","family":"Hainsworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz M.","family":"Beer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"North","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Fradet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas A.","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"De Porre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anil","family":"Londhe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thian","family":"Kheoh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric J.","family":"Small","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Howard I.","family":"Scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arturo","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles J.","family":"Ryan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2015.04.032_bib0150","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1002\/ijc.27711","article-title":"Global estimates of cancer prevalence for 27 sites in the adult population in 2008","volume":"132","author":"Bray","year":"2013","journal-title":"Int J Cancer"},{"key":"10.1016\/j.eururo.2015.04.032_bib0155","doi-asserted-by":"crossref","first-page":"10","DOI":"10.3322\/caac.20138","article-title":"Cancer statistics, 2012","volume":"62","author":"Siegel","year":"2012","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.eururo.2015.04.032_bib0160","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ctrv.2012.09.005","article-title":"Progress in emerging therapies for advanced prostate cancer","volume":"39","author":"Oudard","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.eururo.2015.04.032_bib0165","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S0022-5347(05)00034-0","article-title":"Secondary hormonal therapy for advanced prostate cancer","volume":"175","author":"Lam","year":"2006","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.04.032_bib0170","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1053\/hp.2000.6698","article-title":"Metastatic patterns of prostate cancer: an autopsy study of 1,589 patients","volume":"31","author":"Bubendorf","year":"2000","journal-title":"Hum Pathol"},{"key":"10.1016\/j.eururo.2015.04.032_bib0175","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1007\/s00520-008-0418-0","article-title":"Impact of skeletal complications on patients\u2019 quality of life, mobility, and functional independence","volume":"16","author":"Costa","year":"2008","journal-title":"Support Care Cancer"},{"key":"10.1016\/j.eururo.2015.04.032_bib0180","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1038\/nrurol.2013.137","article-title":"Overview of the latest treatments for castration-resistant prostate cancer","volume":"10","author":"Bishr","year":"2013","journal-title":"Nat Rev Urol"},{"key":"10.1016\/j.eururo.2015.04.032_bib0185","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.04.032_bib0190","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.eururo.2015.04.032_bib0195","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.eururo.2015.04.032_bib0200","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1002\/cncr.20056","article-title":"Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies","volume":"100","author":"Diamond","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.04.032_bib0205","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.04.032_bib0210","doi-asserted-by":"crossref","first-page":"210686","DOI":"10.1155\/2013\/210686","article-title":"Bone-targeted therapies in metastatic castration-resistant prostate cancer: evolving paradigms","volume":"2013","author":"El-Amm","year":"2013","journal-title":"Prostate Cancer"},{"key":"10.1016\/j.eururo.2015.04.032_bib0215","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.canlet.2012.04.001","article-title":"Bone-targeting radiopharmaceuticals for the treatment of prostate cancer with bone metastases","volume":"323","author":"Goyal","year":"2012","journal-title":"Cancer Lett"},{"key":"10.1016\/j.eururo.2015.04.032_bib0220","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.clgc.2012.07.002","article-title":"Two-year survival follow-up of the randomized, double-blind, placebo-controlled phase II study of radium-223 chloride in patients with castration-resistant prostate cancer and bone metastases","volume":"11","author":"Nilsson","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"10.1016\/j.eururo.2015.04.032_bib0225","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1158\/1078-0432.CCR-10-2815","article-title":"Targeting continued androgen receptor signaling in prostate cancer","volume":"17","author":"Massard","year":"2011","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.eururo.2015.04.032_bib0230","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1016\/j.juro.2010.10.042","article-title":"Novel therapeutic strategies for castration resistant prostate cancer: inhibition of persistent androgen production and androgen receptor mediated signaling","volume":"185","author":"Molina","year":"2011","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2015.04.032_bib0245","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1056\/NEJMoa1209096","article-title":"Abiraterone in metastatic prostate cancer without previous chemotherapy","volume":"368","author":"Ryan","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eururo.2015.04.032_bib0255","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1016\/j.eururo.2014.02.056","article-title":"Updated interim efficacy analysis and long-term safety of abiraterone acetate in metastatic castration-resistant prostate cancer patients without prior chemotherapy (COU-AA-302)","volume":"66","author":"Rathkopf","year":"2014","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2015.04.032_bib0250","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1016\/S1470-2045(13)70424-8","article-title":"Abiraterone acetate plus prednisone versus prednisone alone in chemotherapy-naive men with metastatic castration-resistant prostate cancer: patient-reported outcome results of a randomised phase 3 trial","volume":"14","author":"Basch","year":"2013","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2015.04.032_bib0260","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.032_bib0265","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1007\/s11136-006-9156-2","article-title":"Quality of life findings from a multicenter, multinational, observational study of patients with metastatic hormone-refractory prostate cancer","volume":"16","author":"Sullivan","year":"2007","journal-title":"Qual Life Res"},{"key":"10.1016\/j.eururo.2015.04.032_bib0270","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/SPC.0b013e328356da87","article-title":"Preventing bone complications in prostate cancer","volume":"6","author":"Bishr","year":"2012","journal-title":"Curr Opin Support Palliat Care"},{"issue":"Suppl 5","key":"10.1016\/j.eururo.2015.04.032_bib0275","article-title":"Pain control and delay in time to skeletal-related events (SREs) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone acetate (AA): long-term follow-up","volume":"30","author":"Basch","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.eururo.2015.04.032_bib0280","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/S1470-2045(12)70473-4","volume":"13","author":"Logothetis","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.eururo.2015.04.032_bib0285","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1002\/cncr.23529","article-title":"Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid","volume":"113","author":"Lipton","year":"2008","journal-title":"Cancer"},{"key":"10.1016\/j.eururo.2015.04.032_bib0290","doi-asserted-by":"crossref","first-page":"390","DOI":"10.3816\/CGC.2007.n.022","article-title":"Continuing benefit of zoledronic acid in preventing skeletal complications in patients with bone metastases","volume":"5","author":"Saad","year":"2007","journal-title":"Clin Genitourin Cancer"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815003747?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283815003747?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T01:02:25Z","timestamp":1668646945000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283815003747"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,10]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2015,10]]}},"alternative-id":["S0302283815003747"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2015.04.032","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2015,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Impact of Bone-targeted Therapies in Chemotherapy-na\u00efve Metastatic Castration-resistant Prostate Cancer Patients Treated with Abiraterone Acetate: Post Hoc Analysis of Study COU-AA-302","name":"articletitle","label":"Article Title"},{"value":"European Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eururo.2015.04.032","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2015 European Association of Urology. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}